Celgene Corp (CELG)

137.74
1.43 1.05
NASDAQ : Health Care
Prev Close 136.31
Open 136.23
Day Low/High 135.72 / 138.17
52 Wk Low/High 92.98 / 137.54
Volume 3.64M
Avg Volume 3.97M
Exchange NASDAQ
Shares Outstanding 780.82M
Market Cap 105.41B
EPS 2.60
P/E Ratio 50.75
Div & Yield N.A. (N.A)

Latest News

Risk Happens Fast: Doug Kass

Risk Happens Fast: Doug Kass

What you need to know.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

Summer Watch List: How Some Key Names Are Stacking Up

Here's what to focus on from these stocks in July.

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers

The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration With BeiGene To Advance PD-1 Inhibitor Program For Solid Tumor Cancers

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration With BeiGene To Advance PD-1 Inhibitor Program For Solid Tumor Cancers

Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene's investigational anti-programmed cell death protein 1 (PD-1) inhibitor,...

Celgene Stock Will Continue to Rise on MS Drug's Success: Leerink

Celgene Stock Will Continue to Rise on MS Drug's Success: Leerink

Leerink analysts see Celgene continuing in an upward trend as its new multiple sclerosis drug ozanimod differentiates itself from a competitive field.

Celgene Corporation To Announce Second Quarter 2017 Results On July 27, 2017

Celgene Corporation To Announce Second Quarter 2017 Results On July 27, 2017

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 27, 2017 at 9 a.

Another Steep Selloff in Tech Stocks Wipes Out Nasdaq's June Gains

Another Steep Selloff in Tech Stocks Wipes Out Nasdaq's June Gains

A tech selloff yields big Wall Street losses.

Oracle Re-rating; No Country for Old Value: Jim Cramer's View

Oracle Re-rating; No Country for Old Value: Jim Cramer's View

Cramer shares his views on Oracle's re-rating and also discusses the constant battle between growth and value.

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

Celebrated Photographer Martin Schoeller Shines A Light On People With Psoriatic Disease Including Olympic Swimmer And Author Dara Torres As Part Of Celgene's SHOW MORE OF YOU Campaign

Award-winning portrait photographer Martin Schoeller along with 12-time Olympic medalist and New York Times best-selling author Dara Torres and others with psoriatic disease have come together for the SHOW MORE OF YOU...

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Growth is crushing value, says Jim Cramer, and the dynamic is more pronounced in individual sectors.

Celgene Is Headed Much Higher Even After a Monster Breakout

Celgene Is Headed Much Higher Even After a Monster Breakout

Biotechs are hot.

Cramer: This Is No Country for Old Value

Cramer: This Is No Country for Old Value

Down-and-out stocks have become toxic.

All the Rallying Big Bank Stocks Look Very Risky, Doug Kass Says

All the Rallying Big Bank Stocks Look Very Risky, Doug Kass Says

Doug Kass shares his thoughts on Apple, Google and Starbucks.

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.